Every controlled substance prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice, the standard set out at 21 CFR 1306.04(a). When the Drug Enforcement Administration investigates a prescriber, its case can rest on a review of the patient files and what they document. In a July 2025 decision, DEA revoked a Florida physician's registration after he defaulted and was deemed to have admitted issuing controlled substance prescriptions without medical examinations, bona fide physician-patient relationships or proper medical records. The agency found that at least 18 controlled substance prescriptions lacked a legitimate medical purpose, and its decision lists the Florida documentation requirements it applied.
The Legitimate Medical Purpose Standard
21 CFR 1306.04(a) provides that a prescription for a controlled substance is effective only if issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. The regulation places the responsibility for proper prescribing on the prescriber and a separate corresponding responsibility on the pharmacist who fills the prescription; Health Law Alliance covers the pharmacist's side of that duty separately. DEA decisions say a practitioner must establish and maintain a bona fide doctor-patient relationship to act in the usual course of professional practice. In administrative proceedings, DEA has examined the prescriber's own patient files for a documented examination or evaluation, a recognized medical indication, and the rationale for the prescribing.
What DEA Reads the Chart For
DEA's public interest determination weighs a registrant's compliance with applicable state, federal, or local laws relating to controlled substances under 21 U.S.C. Section 823(g)(1), so a state's prescribing law is among the laws DEA weighs. In the Florida case, the agency pointed to Florida law requiring a complete medical history and physical examination, a written treatment plan with goals and objectives, a discussion of risks and benefits with the patient, visits at regular intervals, and ongoing monitoring of the patient's risk for aberrant drug-related behavior, with records detailed enough to clearly demonstrate why the course of treatment was undertaken. The recordkeeping rules for controlled substance inventories, ordering records and theft and loss reports are a related but separate requirement, covered for pharmacies in DEA Recordkeeping: The Audit-Ready Controlled Substance File; this article addresses the clinical record a chart must show, not the registration paperwork.
Recurring Documentation Gaps
The Florida matter did not turn on a close reading of a chart: the physician defaulted and was deemed to have admitted issuing prescriptions without medical examinations, bona fide physician-patient relationships or proper medical records. The same standard applies to closer questions: a dose increase, a quantity larger than the patient's history would suggest, or a refill issued before the prior fill's days'-supply would have run out. In a 2022 decision denying a California physician's application, DEA relied on a physician it hired to review the patient files, who found no documentation that the applicant had adequately addressed or resolved a patient's early refills. A 2006 DEA policy statement lists recurring patterns courts have found in improper prescribing cases, among them an inordinately large quantity, no physical examination, and prescribing at intervals inconsistent with legitimate medical treatment, and adds that none of these automatically leads to the conclusion that the physician acted improperly.
Correcting the Record Without Altering Closed Entries
A documentation gap discovered internally is not fixed by rewriting the original note. Medicare's Program Integrity Manual says the date and author of any amendment, correction or delayed entry should be identifiable and the change clearly and permanently denoted, and Florida's medical records rule permits late entries only if they are clearly and accurately noted as late entries and accurately dated when entered. Federal law makes it a crime to knowingly alter, falsify or make a false entry in a record with the intent to impede, obstruct or influence the investigation of a matter within a federal agency's jurisdiction (18 U.S.C. 1519). Going forward, the fix is prospective: a documented evaluation, a stated treatment rationale, and a monitoring note at each interval, entered contemporaneously rather than reconstructed later.
Florida's rule, as DEA cited it in the 2025 decision, requires medical records with sufficient detail to clearly demonstrate why the course of treatment was undertaken.
Why Early Legal Counsel Is Critical
It is critical that prescribers promptly retain experienced healthcare defense counsel upon receiving a DEA subpoena, a records request, or notice that a registration action may follow. Early legal intervention can protect the prescriber's rights, guide how documentation gaps are addressed without altering closed entries, avoid inadvertent admissions during an interview or records production, and allow counsel to communicate with the Diversion Control Division on the prescriber's behalf. Delaying representation narrows the options once DEA issues a DEA order to show cause, the formal notice proposing to revoke or deny a registration, or escalates to an immediate suspension order where the agency finds an imminent danger to public health or safety; the response process is covered separately in Responding to a DEA Order to Show Cause.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have handled 5,000+ matters, with 25+ years of experience. If DEA has requested records, issued a subpoena, or proposed a registration action tied to your prescribing pattern, contact Health Law Alliance's DEA defense attorneys for a free, confidential consultation before you respond.
